Analyst firms · Morgan Stanley · NEO

Morgan Stanley NEO price target and rating history

NeoGenomics Inc. (NEO) · Health Care

Morgan Stanley rates NeoGenomics Inc. (NEO) Equal-Weight with a $29 price target, as of its latest action on Feb 24, 2022. It has published 3 rating actions on NEO since August 2021, including 0 upgrades and 1 downgrade.

Current rating
Equal-Weight
Price target
$29
Median target, all firms
Too few
Actions on NEO
3

Morgan Stanley price target on NEO

$32$29$2620222023202420252026
Morgan Stanley price target on NEO, each point a stated target, August 2021 to February 2022. Targets before February 2022 (divided by 2) are adjusted for a stock split, going by the prior target Morgan Stanley restated.

Every Morgan Stanley rating on NEO

How other firms rate NEO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BTIGBuy$28Oct 6, 2026
Leerink PartnersOutperform$25Apr 29, 2026

Questions about Morgan Stanley and NEO

What is Morgan Stanley's price target for NEO?
Morgan Stanley's latest stated price target for NeoGenomics Inc. (NEO) is $29, from its action on Feb 24, 2022.
What is Morgan Stanley's rating on NEO?
Morgan Stanley rates NEO Equal-Weight, a neutral rating, as of Feb 24, 2022.
When did Morgan Stanley last change its view on NEO?
On Feb 24, 2022, Morgan Stanley cuts its price target to $29 from $30, keeps Equal-Weight.

More NEO rating histories

All Morgan Stanley ratingsNEO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.